COMPLETEDPHASE4

Montelukast as a Controller of Atopic Syndrome

NCT00559546•University of Helsinki

View on ClinicalTrials.gov

Summary

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

Eligibility

Age

18 - 40 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Wheal diameter at least 4 mm in skin-prick test for both birch and timothy
•Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following:
•* Allergic conjunctivitis
•* Atopic eczema
•* Oral symptoms from vegetables or fruits by cross reactivity to birch
•* Urticaria in allergen exposure

Exclusion Criteria

•Need for regular treatment with glucocorticoids
•Current smoking
•Other major disease or need for regular drug treatment
•Pregnancy

Locations (1)

Skin and Allergy Hospital, Helsinki University Hospital

Helsinki, Finland

Key Dates

Start Date

March 1, 2007

Completion Date

July 1, 2007

Last Updated

November 16, 2007

Enrollment

61

ACTUAL participants

Conditions

Seasonal Allergic RhinitisAllergic ConjunctivitisAtopic EczemaAsthma

Interventions

montelukast

DRUG

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

NCT06453512

Atopic Eczema

View study

RECRUITING

TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies

NCT03621137

Moderate-to-severe Atopic Eczema

View study

ENROLLING_BY_INVITATIONNA

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 16, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT05839938

Allergic Conjunctivitis

View study

ACTIVE_NOT_RECRUITING